The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor Markets

AstraZeneca Wins FDA Priority Review for Gastric Drug

By The Daily Byte ·21 Nov 2026 ·3 min read
AstraZeneca's global headquarters building in Cambridge

AstraZeneca has won priority review from the US Food and Drug Administration for its experimental gastric cancer drug sonesitatug vedotin, known as Sone-Ve, in a decision that shortens the path to a potential new targeted treatment for patients with few options.

The company said on Thursday that the FDA had accepted its biologics licence application for Sone-Ve and granted it priority review, a status reserved for medicines that could offer a significant improvement over existing treatments. A decision is expected in the second quarter of 2027.

The application covers the second-line and later treatment of locally advanced or metastatic gastric, gastroesophageal junction and oesophageal adenocarcinoma in patients whose tumours express the protein Claudin 18.2 on at least 25% of tumour cells.

What the trial showed

The filing is based on results from the Phase III CLARITY-Gastric01 trial, a global study conducted at 175 centres in 19 countries and presented at the 2026 European Society for Medical Oncology congress.

In the trial, Sone-Ve reduced the risk of death by 42% compared with the investigator's choice of therapy, with median overall survival of 10.6 months against 6.4 months. In patients treated in the third line or later, the benefit was larger still: median overall survival of 10.0 months against 5.0 months, a 53% reduction in the risk of death.

Progression-free survival also improved, to 4.2 months from 3.8 months, and the safety profile was manageable. Grade 3 or higher adverse events occurred in 52.9% of patients who received Sone-Ve, compared with 61.1% of those on the investigator's choice of treatment, and no new safety signals were seen. Nausea, decreased appetite and vomiting were more common with Sone-Ve, while severe neutropenia, a low white blood cell count, was less common.

A first for this target

Sone-Ve is an antibody-drug conjugate designed to seek out Claudin 18.2, a protein found in a large share of gastroesophageal cancers, and deliver a cell-killing drug directly to the tumour. Susan Galbraith, AstraZeneca's executive vice president of oncology haematology research and development, said it was the first drug of its kind targeting Claudin 18.2 to improve overall survival in this setting.

"After progressing on first-line treatment, patients with Claudin 18.2-positive advanced gastric cancer have no targeted options," she said. "This priority review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the United States."

The drug holds orphan drug designation from the FDA and the European Commission for gastric and gastroesophageal junction cancers, and a breakthrough designation in China for second-line gastric cancer. AstraZeneca added Sone-Ve to its pipeline through a global licensing agreement with KYM Biosciences in March 2023, and applications are also under review in the European Union, China and other countries.

What happens next

Investors will now watch for the FDA's decision in the second quarter of 2027, and for further data on how Sone-Ve performs in combination with other treatments. The drug is also being studied alongside capecitabine-based chemotherapy, which could widen its use if the results are positive.

For AstraZeneca, the priority review adds a fresh oncology catalyst to a pipeline that has become the engine of the company's growth. Gastric cancer remains one of the hardest cancers to treat once it has spread, and a targeted option for patients who have already had first-line therapy would fill a clear gap in care.

The shares were caught in Friday's broad market sell-off, but the regulatory step itself was the day's substantive news for the company: a defined, dated milestone that investors can now track into the middle of next year.